Correction to: Eye
Since online publication of this article, the authors became aware of two errors in the text of the manuscript:
-
1.
Page 1 Paragraph 1, an incorrect approval date was inserted. The correct sentence is provided below:
Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. lt was approved for the treatment of neovascular age-related macular degeneration (nAMD) by the US-FDA on October 7, 2019, followed by the European Commission’s approval for use in the European Union on February 13, 2020.
-
2.
Page 2 Paragraph 1, an incorrect percentage was provided. The correct sentence is provided below:
Pigment epithelial detachment (PED) was present in 31 eyes (73.8%) at baseline and resolved in 2 eyes (6.4%), was reduced in 13 eyes (41.9%\, and did not show any change in 16 eyes (51.6%) (Fig. 1).
The authors apologise for any inconvenience caused.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41433-020-1111-x.
Rights and permissions
About this article
Cite this article
Sharma, A., Kumar, N., Parachuri, N. et al. Correction: Brolucizumab—early real-world experience: BREW study. Eye 35, 1286 (2021). https://doi.org/10.1038/s41433-020-01351-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-020-01351-7
